1[1]Schiller JH. Influential papers since the last IASLC conference: cytotoxic therapy. Lung Cancer,2003,41(Suppl 3)∶S86. 被引量：1
2[2]Socinski MA. Optimal number of cytotoxic agents and chemotherapy cycles for advanced NSCLC. Lung Cancer,2003, 41(Suppl 3)∶S93. 被引量：1
3[3]Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol,2001,19(5)∶1336-1343. 被引量：1
4[4]Socinski MA, Schell MJ, Peterman A, et al. Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage ⅢB/Ⅳ non-small-cell lung cancer. J Clin Oncol,2002,20(5)∶1335-1343. 被引量：1
5[5]Depierre A, Quoix E, Mercier M, et al. Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized study of vinorelbine (v) versus observation (ob) in patients (pts) responding to induction therapy (French Cooperative Oncology Group). Proc Am Soc Clin Onc,2001,20p∶309a. 被引量：1
6[6]Fukuoka M. Epidermal growth factor receptor tyrosine kinase inhibitors: single agent therapy. Lung Cancer,2003,41(Suppl 3)∶S38. 被引量：1
7[7]Goss G. Gefitinib ("Iressa"): The patients' experience. Lung Cancer,2003,41(Suppl 3)∶112. 被引量：1
8[8]Herbst RS. Targeting the EGFR: prognostic and clinical implications. Lung Cancer,2003,41(Suppl 3)∶S114. 被引量：1
9[9]Lynch T. Clinical benefit in NSCLC: The evidence for gefitinib ("Iressa"). Lung Cancer,2003,41(Suppl 3)∶S116. 被引量：1
10[10]Hidalgo M. TarcevaTM: a potent HER1/EGFR-tyrosine kinase inhibitor. Lung Cancer,2003,41(Suppl 3)∶S115. 被引量：1
